Compare Flagstar Bank NA (FLG) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flagstar Bank NA vs Sanofi SA — how do they compare? Flagstar Bank NA trades at $14.19 (market cap $5.89B), while Sanofi SA trades at $43.71 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 17.7× Flagstar Bank NA's market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| FLG | SNY | |
|---|---|---|
Market Cap | $5.89B | $104.30B |
Sector | Financials | Health |
52-Week High | $15.36 | $52.34 |
52-Week Low | $10.72 | $41.33 |
Dividend Yield | 0.28% | 5.55% |
Enterprise Value | — | $124.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLG trades at $14.20, up 1.36% today, with a bullish technical signal and analyst consensus price target of $16.85 suggesting 19% upside. Recent Q2 2026 earnings missed estimates, but the bank reported its third consecutive profitable quarter, supported by loan growth and cost controls. A $250 million share repurchase program and strategic operational enhancements signal management confidence in long-term value.
The outlook is cautiously optimistic, with profitability improving and valuation attractive at a P/B of 0.77. Risks include earnings volatility, competitive pressures, and economic sensitivity. Institutional sentiment leans bullish, with no sell ratings, though execution on guidance remains key for sustained momentum.
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
